Aethlon Medical Inc. initiated a research study to validate the ability of its Hemopurifier product in capturing viruses that are associated with increased mortality in immune-suppressed sepsis patients.

The study is designed to validate the in vitro capture of cytomegalovirus, Epstein-Barr virus and herpes simplex viruses.

Aethlon will seek to demonstrate that Hemopurifier can simultaneously capture all three viruses after completion of this study.

The Hemopurifier is being advanced in FDA-approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens.

Separately, Aethlon recently completed a sepsis-related contract for the U.S. Department of Defense's Defense Advanced Research Projects Agency. Under this program, the company achieved all 29 milestone opportunities in the program, generating about $5.9 million in revenues over the life of the contract.